Tardive dyskinesia

Cover Page

Cite item

Full Text

Abstract

Tardive dyskinesia is a group of hyperkinetic and hypokinetic movement disorders, following the administration of dopamine receptor-blocking drugs. The severity of these syndromes varies from soft forms to the development of life-degrading situations. Phenomenologically tardive dyskinesia can be represented both in isolation and in various combinations. Recognition of these syndromes early in the development of tardive dyskinesia can optimize therapeutic treatment and reduce the risk of severe complications. As a means of treatment, deutetrabenazine or valbenazine are used as first-line drugs, with resistance to therapy and in severe cases, drugs of other groups are used (amantadine, baclofen, botulinum toxin type A, clonazepam, donepezil, gabapentin, ginkgo biloba, levetiracetam, melatonin, pregabalin, thiamine, verapamil, vitamin B6, vitamin E). Our own experience of 12 patients with tardive dystonia showed the effeciency of local injections of botulinum toxin.

About the authors

Violetta A. Tolmacheva

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: vtolmacheva@yandex.ru
ORCID iD: 0000-0002-8115-2668

Cand. Sci. (Med.)

Russian Federation, Moscow

References

  1. Frei K, Truong DD, Fahn S, et al. The nosology of tardive syndromes. J Neurol Sci. 2018;389:10-6. doi: 10.1016/j.jns.2018.02.008
  2. American Psychiatric Association. Medication-induced movement disorders and other adverse effects of medication. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: American Psychiatric Association, 2013.
  3. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76:779-87. doi: 10.1007/s40265-016-0568-1
  4. Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache. 2016;56:153-61. doi: 10.1111/head.12712
  5. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1. doi: 10.7916/D88P5Z71
  6. Association AP. Diagnostic and statistical manual of mental disorders, revised (DSM-5). Fifthed, 2019.
  7. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486-7. doi: 10.1001/archpsyc.1982.04290040080014
  8. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol. 1991;11:34-42.
  9. Rodnitzky RL. Drug-unduced movement disorders in children and adolescents. Expert Opin Drug Saf. 2005;4:91-102. doi: 10.1517/14740338.4.1.91
  10. McCreadie RG, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia 18-month follow-up. Br J Psychiatry. 2002;181:135-7.
  11. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61(Suppl. 4):10-4.
  12. Revuelta GJ, Cloud LJ, Aia PG, Factor SA. Tardive dyskinesia. In: Albanese AJ, editor. Hyperkinetic movement disorders: diagnosis, etiology, and treatment. Oxford, England: Wiley Blackwell, 2012; p. 331-52.
  13. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010;4(1):56-73. doi: 10.3371/CSRP.4.1.5
  14. Ali Z, Roque A, El-Mallakh RS. A unifying theory for the pathoetiologic mechanism of tardive dyskinesia. Med Hypotheses. 2020;140:109682. doi: 10.1016/j.mehy.2020.109682
  15. Blanchet PJ, Parent MT, Rompre PH, Levesque D. Relevance of animal models to human tardive dyskinesia. Behav Brain Funct. 2012;8:12. doi: 10.1186/1744-9081-8-12
  16. Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162-74.
  17. Jensen N, Oliveira JRM. Basal ganglia vulnerability to oxidative stress. Front Neurosci. 2014;8:80. doi: 10.3389/fnins.2014.00080
  18. Martins MR, Petronilho FC, Gomes KM, et al. Antipsychotic-induced oxidative stress in rat brain. Neurotox Res. 2008;13(1):63-9. doi: 10.1007/BF03033368
  19. Casey DE, Gerlach J, Magelund G, Christensen TR. Gamma-acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry. 1980;37(12):1376-9. doi: 10.1001/archpsyc.1980.01780250062007
  20. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-48. doi: 10.1016/j.ncl.2010.10.002
  21. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardivedyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541-7. doi: 10.1177/070674370505000907
  22. Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord. 2019;59:151-4. doi: 10.1016/j.parkreldis.2018.11.017
  23. Fahn S, Jankovic J, Hallett M. The tardive syndromes: Phenomenology, concepts on pathophysiology and treatment, and other neuroleptic-induced syndromes. In: Fahn S, Jankovic J, Hallett M, editors. Principles and practice of movement disorders, 2nd ed. Philadelphia, PA: ElsevierSanders, 2011; p. 415-46.
  24. Guy W. Abnormal Involuntary Movements Scale (AIMS) ECDEU assessment manual for psychpharmacology. Washington, DC: United States Government Printing Office, 1976; p. 534-7.
  25. Kruk J, Sachev P, Singh S. Neuroleptic-induced respiratory dyskinesia. J Neuropsychiatry Clin Neurosci. 1995;7:223-9. doi: 10.1176/jnp.7.2.223
  26. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335-46. doi: 10.1212/wnl.32.12.1335
  27. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management. CNS Drugs. 2002;16(3):165-74. doi: 10.2165/00023210-200216030-00003
  28. Stubner S, Padberg F, Grohmann R, et al. Pisa syndrome (pleurothotonus): report of a multicentre drug safety surveillance project. J Clin Psychiatry. 2000;61:569-74.
  29. Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4(2):157-75. doi: 10.1002/mds.870040208
  30. Van Putten T, May PR, Marder SR. Akathisia with haloperidol and thithixene. Arch Gen Psychiatry. 1984;41:1036-9. doi: 10.1001/archpsyc.1983.01790220026004
  31. Kuloglu M, Atmaca M, Ustundag B, et al. Serum iron levels in schizophrenic patients with or without akathisia. Eur Neuro psychopharmacol. 2003;13:67-71. doi: 10.1016/s0924-977x(02)00073-1
  32. Barnes TR, Braude WM. Persistent akathisia associated with early tardive dyskinesia. Postgrad Med J. 1984;60(703):359-61. doi: 10.1136/pgmj.60.703.359
  33. Klawans HL, Falk DK, Nausieda PA, Weiner WJ. Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology. 1978;28(10):1064-6. doi: 10.1212/wnl.28.10.106
  34. Little JT, Jankovic J. Tardive myoclonus. Mov Disord. 1987;2(4):307-11. doi: 10.1002/mds.870020408
  35. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993;43:937-41. doi: 10.1212/wnl.43.5.937
  36. Schwartz M, Hocherman S. Antipsychotic-induced rabbit syndrome: epidemiology, management and pathophysiology. CNS Drugs. 2004;18:213-20. doi: 10.2165/00023210-200418040-00002
  37. Glazer WM, Morgenstern H, Schooler N, et al. Predictions of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585-92. doi: 10.1192/bjp.157.4.585
  38. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75. doi: 10.1016/j.jns.2018.02.010
  39. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463-9. doi: 10.1212/WNL.0b013e31829d86b6
  40. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003-10. doi: 10.1212/WNL.0000000000003960
  41. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476-84. doi: 10.1176/appi.ajp.2017.16091037
  42. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:1342-8.
  43. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445-51. doi: 10.1176/ajp.147.4.445
  44. Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:615-21. doi: 10.4088/JCP.09m05125yel
  45. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88-91. doi: 10.1097/00004714-199704000-00004
  46. Decker BL, Davis JM, Jonowsky DS, et al. Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med. 1971;285(15):860. doi: 10.1056/NEJM197110072851516
  47. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130:479-83. doi: 10.1176/ajp.130.4.479
  48. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279-81. doi: 10.1176/ajp.156.8.1279
  49. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;2:CD000209. doi: 10.1002/14651858.CD000209.pub2
  50. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006;1:CD000458. doi: 10.1002/14651858.CD000458.pub2
  51. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;11:CD000206. doi: 10.1002/14651858.CD000206.pub3
  52. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015;4:CD010501. doi: 10.1002/14651858.CD010501.pub2
  53. Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology. 2016;86:651-9. doi: 10.1212/WNL.0000000000002370
  54. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974;37(8):941-7. doi: 10.1136/jnnp.37.8.941
  55. Fernandez HH, Friedman JH. Сlassification and treatment of tardive syndromes. Theneurologist. 2003;9:16-27. doi: 10.1097/01.nrl.0000038585.58012.97
  56. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;121(Pt. 11):2053-66. doi: 10.1093/brain/121.11.2053
  57. Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs. 1999;11:467-83.
  58. Dressler D, Oeljeschlager RD, Ruther E. Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov Disord. 1997;12(4):585-7. doi: 10.1002/mds.870120416
  59. Kupsch A, Kuehn A, Klaffke S, et al. Deep brain stimulation in dystonia. J Neurol. 2003;250(Suppl. 1):I47-52. doi: 10.1007/s00415-003-1110-2

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies